文献速递浆细胞疾病

泊马度胺、硼替佐米和地塞米松治疗复发来那度胺难治性多发性骨髓瘤患者

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
PubMed 文献 · Blood · 2017-07-06

这项1/2期试验评估泊马度胺、硼替佐米和地塞米松(PVD)联合方案在复发来那度胺难治性多发性骨髓瘤(MM)患者中的最大耐受剂量、安全性和疗效。共描述50例患者,客观缓解率86%(95%CI 73-94),高危患者100%;中位随访42个月,中位无进展生存期13.7个月(95%CI 9.6-17.7)。结论认为PVD是来那度胺难治性MM患者的高效联合方案,硼替佐米每周给药提高了耐受性和便利性,毒性可控,主要为轻度血细胞减少,无显著神经病变。

要点

  • PVD方案在来那度胺难治性MM中客观缓解率86%,高危患者100%。
  • 中位无进展生存期13.7个月,中位随访42个月时66%存活。
  • 常见毒性为血细胞减少,多为1-2级,无显著神经病变。

主要发现

  • 所有可评估患者客观缓解率86%(95%CI 73-94),其中严格完全缓解12%、完全缓解10%、非常好的部分缓解28%、部分缓解36%。
  • 高危患者客观缓解率100%。
  • 中位随访42个月时,20%无进展,66%存活,4%仍在治疗。
  • 中位无进展生存期13.7个月(95%CI 9.6-17.7)。
  • 最常见毒性为中性粒细胞减少(96%)、白细胞减少(84%)、血小板减少(82%)、贫血(74%)和疲乏(72%),但多数为1或2级;最常见≥3级毒性包括中性粒细胞减少(70%)、白细胞减少(36%)和淋巴细胞减少(20%);深静脉血栓发生5例。

关键数值与推荐

  • 1期剂量水平1:泊马度胺4 mg口服,第1-21天;硼替佐米1.0 mg/m2静脉或皮下,第1、8、15、22天;地塞米松40 mg口服,第1、8、15、22天;每28天为一周期。
  • 2期扩展队列采用剂量水平2:硼替佐米增至1.3 mg/m2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 1/2 trial evaluated the maximum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combination in patients with relapsed lenalidomide-refractory multiple myeloma (MM). In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21), IV or subcutaneous bortezomib (1.0 mg/m2 on days 1, 8, 15, and 22), and dexamethasone (40 mg by mouth on days 1, 8, 15, and 22) given every 28 days. Bortezomib was increased to 1.3 mg/m2 for dose level 2 and adopted in the phase 2 expansion cohort. We describe the results of 50 patients. Objective response rate was 86% (95% confidence interval [CI], 73-94) among all evaluable patients (stringent complete response, 12%; complete response, 10%; very good partial response, 28%; and partial response, 36%) and 100% among high-risk patients. Within a median follow-up of 42 months, 20% remain progression free, 66% are alive, and 4% remain on treatment. Median progression-free survival was 13.7 months (95% CI, 9.6-17.7). The most common toxicities were neutropenia (96%), leukopenia (84%), thrombocytopenia (82%), anemia (74%), and fatigue (72%); however, the majority of these were grade 1 or 2. The most common grade ≥3 toxicities included neutropenia (70%), leukopenia (36%), and lymphopenia (20%). Deep vein thrombosis occurred in 5 patients. In conclusion, PVD is a highly effective combination in lenalidomide-refractory MM patients. Weekly administration of bortezomib enhanced tolerability and convenience. Toxicities are manageable, mostly consisting of mild cytopenias with no significant neuropathy. This trial was registered at www.clinicaltrials.gov as #NCT01212952.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Paludo J, Mikhael JR, LaPlant BR, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017. PMID: 28684537. doi:10.1182/blood-2017-05-782961

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。